抗增殖蛋白2对脓毒症心肌损伤线粒体功能稳态的作用机制研究

doi:10.20223/j.cnki.1000-8535.2025.09.006

摘要/Abstract

摘要： 目的探讨抗增殖蛋白2（PHB2）脓毒症心肌损伤线粒体功能的调控机制。方法体外培养大鼠心肌细胞株（H9C2）,分为对照组、脂多糖（LPS）组、LPS+PHB2 siRNA（si-PHB2）组。检测氧化应激指标细胞内丙二醛（MDA）水平、荧光探针检测细胞内活性氧（ROS）水平;线粒体指标：三磷酸腺苷（ATP）水平、线粒体膜电位、线粒体电镜、线粒体半定量评分;免疫印迹法检测PHB2、PTEN诱导激酶1（PTNKI）、帕金蛋白（Parkin）、线粒体转录因子（TFAM）的表达。结果 LPS刺激后MDA水平和ROS水平升高、ATP水平低,LPS+si-PHB2组MDA（6.21±0.39 vs 3.59±0.33,P<0.05）、细胞内的ROS（15 131.37±88.72 vs 8 628.67±71.95,P<0.05）的水平较LPS组升高,ATP（3.46±0.34 vs 4.52±0.25,P<0.05）和线粒体膜电位水平（0.33±0.04 vs 0.55±0.09,P<0.05）进一步降低;电镜观察显示与正常组相比,LPS组、LPS+si-PHB2组出现不同程度线粒体损伤,线粒体损伤半定量评分显示LPS+si-PHB2组的损伤较LPS组更为明显（1.42±0.10 vs 0.81±0.04,P<0.05）;免疫印迹法结果显示LPS处理后PHB2、PINK1、Parkin 表达上调,TFAM表达下调,LPS+si-PHB2组的线粒体自噬相关蛋白PINK1（1.33±0.06 vs 1.79±0.21,P<0.05）、Parkin（1.43±0.08 vs 1.86±0.09,P<0.05）和线粒体生物发生关键蛋白TFAM（0.29±0.01 vs 0.74±0.06,P<0.05）表达均较LPS组降低。结论 LPS可促进大鼠心肌细胞PHB2表达,si-PHB2干扰后线粒体自噬蛋白和生物发生蛋白表达抑制,心肌细胞氧化应激损害和线粒体功能障碍加重,提示PHB2表达上调可能恢复线粒体稳态改善脓毒症心肌损伤的线粒体功能。

关键词: 脓毒症, 心肌损伤, 线粒体, 抗增殖蛋白2

Abstract: Objective To explore the regulatory mechanism of septic myocardial injury by prohibitin 2（PHB2）. Methods Rat myocardial cell lines（H9C2）were cultured in vitro and divided into control group,LPS group,LPS + PHB2 siRNA（si-PHB2） group. The indicators for detecting oxidative stress include the levels of intracellular malondialdehyde（MDA）and reactive oxygen species（ROS）. The indicators for mitochondrial detection include adenosine triphosphate（ATP）levels,mitochondrial membrane potential,mitochondrial electron microscopy,and semi-quantitative mitochondrial scoring. Western blotting was used to detect the expression of PHB2,PTEN induced putative kinase（PINK1）,Parkin,mitochondrial transcription factor A（TFAM）. Results After LPS stimulation,MDA level and intracellular ROS level increased,ATP level decreased. Compared with LPS group,MDA（6. 21±0. 39 vs 3. 59±0. 33,P<0. 05）level and intracellular ROS level（15 131. 37±88. 72 vs 8 628. 67±71. 95,P<0. 05）in LPS + si-PHB2 group increased significantly,while ATP（3. 46±0. 34 vs 4. 52±0. 25,P<0. 05）and MMP（0. 33±0. 04 vs 0. 55±0. 09,P<0. 05）level further decreased. Compared with the normal group,the structure of mitochondria in LPS group and LPS + si-PHB2 group was damaged in different degree. The semi-quantitative score of mitochondrial damage showed that the damage in LPS + si-PHB2 group was more obvious than that in LPS group（1. 42±0. 10 vs 0. 81±0. 04,P<0. 05）. Western blotting showed that the expression of PHB2,PINK1 and Parkin were up-regulated and the expression of TFAM was down-regulated after LPS treatment,mitohagy-related proteins PINK1（1. 33±0. 06 vs 1. 79±0. 21,P<0. 05）,Parkin（1. 43±0. 08 vs 1. 86±0. 09,P<0. 05）and mitochondrial biogenetic protein TFAM（0. 29±0. 01 vs 0. 74±0. 06,P<0. 05）in LPS+si-PHB2 group were lower than those in LPS group. Conclusions LPS can promote the expression of PHB2 in rat cardiomyocytes. After interfering with PHB2 expression,we found that mitochondrial autophagy and biogenesis are inhibited,and mitochondrial dysfunction,oxidative stress exacerbated,suggesting that the up-regulation of PHB2 expression may restore mitochondrial homeostasis and improve mitochondrial function in septic myocardial injury.

Key words: sepsis, myocardial injury, mitochondria, prohibitin 2

陈志江, 曾成, 赵纬, 韦秋菊, 单文琪, 王惠丽. 抗增殖蛋白2对脓毒症心肌损伤线粒体功能稳态的作用机制研究[J]. 广州医药, 2025, 56(9): 1201-1207.

CHEN Zhijiang, ZENG Cheng, ZHAO Wei, WEI Qiuju, SHAN Wenqi, WANG Huili. Research on the mechanism of prohibitin 2 on mitochondrial functional homeostasis in sepsis-induced myocardial injury[J]. Guangzhou Medical Journal, 2025, 56(9): 1201-1207.

参考文献

[1] BEESLEY S J,WEBER G,SARGE T,et al.Septic cardiomyopathy[J].Crit Care Med,2018,46(4):625-634.
[2] 刘峰宇,孙同文.脓毒症心肌病的诊疗进展[J].中华急诊医学杂志,2022,31(7):858-861.
[3] RAVIKUMAR N,SAYED M A,POONSUPH C J,et al.Septic cardiomyopathy:From basics to management choices[J].Curr Probl Cardiol,2021,46(4):100767.
[4] 白园园,李康保,王思荣.脑钠肽前体和心肌损伤标志物联合监测对老年脓毒症心肌损伤及预后评估的价值[J].广州医药,2016,47(5):33-36.
[5] HOLLENBERG S M,SINGER M.Pathophysiology of sepsis-induced cardiomyopathy[J].Nat Rev Cardiol,2021,18(6):424-434.
[6] 彭慧云. 线粒体与脓毒症多器官功能障碍的研究进展[J].国际儿科学杂志,2015,42(6):677-680.
[7] 郑文炼,王小祥,陈文涛,等.严重烧伤后免疫细胞功能变化和炎症反应之间关系的研究进展[J].广州医药,2023,54(10):1-11.
[8] CIMOLAI M C,ALVAREZ S,BODE C,et al.Mitochondrial mechanisms in septic cardiomyopathy[J].Int J Mol Sci,2015,16(8):17763-17778.
[9] PAN P,WANG X,LIU D.The potential mechanism of mitochondrial dysfunction in septic cardiomyopathy[J].J Int Med Res,2018,46(6):2157-2169.
[10] YE H,HU H,ZHOU X,et al.Targeting ferroptosis in the maintenance of mitochondrial homeostasis in the realm of septic cardiomyopathy[J].Curr Opin Pharmacol,2024(74):102430.
[11] 金光军,喻雯,赵金凯,等.组蛋白去甲基化酶3调控SESN2介导的线粒体自噬在脓毒症心肌损伤中的机制研究[J].浙江医学,2023,45(17):1798-1806,后插1-后插2.
[12] LAHIRI V,KLIONSKY D J.PHB2/prohibitin 2:An inner membrane mitophagy receptor[J].Cell Res,2017,27(3):311-312.
[13] 董艳博,冯红.PHB2(Prohibitin 2)在线粒体中的研究进展[J].天津科技,2018,45(1):36-39.
[14] YAN C,GONG L,CHEN L,et al.PHB2(prohibitin 2)promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis[J].Autophagy,2020,16(3):419-434.
[15] 时颖,李铁松,李庆伟.抗增殖蛋白2:一种线粒体和细胞核之间的重要媒介[J].中国生物化学与分子生物学报,2018,34(1):32-37.
[16] FLAMENG W,BORGERS M,DAENEN W,et al.Ultrastructural and cytochemical correlates of myocardial protection by cardiac hypothermia in man[J].J Thorac Cardiovasc Surg,1980,79(3):413-424.
[17] KOCH R E,JOSEFSON C C,HILL G E.Mitochondrial function,ornamentation,and immunocompetence[J].Biol Rev Camb Philos Soc,2017,92(3):1459-1474.
[18] 王丹,王巍.gC1qR在败血症中的表达及对败血症患者巨噬细胞焦亡和线粒体功能改变的影响[J].国际医药卫生导报,2023,29(1):101-104.
[19] NI H M,WILLIAMS J A,DING W X.Mitochondrial dynamics and mitochondrial quality control[J].Redox Biol,2015(4):6-13.
[20] 陈德,梁譞,牛小伟,等.线粒体质量控制系统与脓毒性心肌病发病机制相关性的研究进展[J].中国急救医学,2022,42(9):803-808.
[21] ALVAREZ S,VICO T,VANASCO V.Cardiac dysfunction,mitochondrial architecture,energy Production,and inflammatory pathways:Interrelated aspects in endotoxemia and sepsis[J].Int J Biochem Cell Biol,2016,81(Pt B):307-314.
[22] JOSEPH L C,REYES M V,LAKKADI K R,et al.PKCδcauses sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction[J].Am J Physiol Heart Circ Physiol,2020,318(4):H778-H786.
[23] NAVARRETE M L,CERDEÑO M C,SERRA M C,et al.Mitochondrial and microcirculatory distress syndrome in the critical patient.Therapeutic implications[J].Med Intensiva,2013,37(7):476-484.
[24] LIU F,ZHANG Y,GUO Z,et al.The role of prohibitin-2 in diseases[J].Front Biosci,2023,28(9):211.
[25] HERNANDO-RODRÍGUEZ B,ARTAL-SANZ M.Mitochondrial quality control mechanisms and the PHB(Prohibitin)complex[J].Cells,2018,7(12):238.
[26] WEI Y,CHIANG W C,SUMPTER R J,et al.Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor[J].Cell,2017,168(1-2):224-238.e10.
[27] HAUSER C J,OTTERBEIN L E.Danger signals from mitochondrial DAMPS in trauma and post-injury sepsis[J].Eur J Trauma Emerg Surg,2018,44(3):317-324.
[28] RAJAEE A,BARNETT R,CHEADLE W G.Pathogen- and danger-associated molecular patterns and the cytokine response in sepsis[J].Surg Infect,2018,19(2):107-116.